Being able to better define the population of patients that might benefit from targeted HER2 therapy with the antibody drug conjugate trastuzumab deruxtecan would facilitate the identification of the subgroup of breast cancer patients for whom a re-analysis of HER2 expression is particularly important. This evidence concerns the gene ERBB2 and breast cancer.